<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01374854</url>
  </required_header>
  <id_info>
    <org_study_id>UCMSC-T1DM</org_study_id>
    <nct_id>NCT01374854</nct_id>
  </id_info>
  <brief_title>Umbilical Mesenchymal Stem Cells and Mononuclear Cells Infusion in Type 1 Diabetes Mellitus</brief_title>
  <official_title>Umbilical Mesenchymal Stem Cells and Mononuclear Cells Infusion in Type 1 Diabetes Mellitus: A Randomized Controlled Open-label Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fuzhou General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fuzhou General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Umbilical mesenchymal stem cells (UC-MSCs) infusion is supposed be a promising regeneration&#xD;
      therapy with mild side effect as indicated by large quantities of animal experiments and some&#xD;
      clinical trials. There are few UC-MSCs clinical trials with regard to diabetes mellitus. The&#xD;
      investigators hypothesize that infusion of USC-MSCs may provide multiple signals for&#xD;
      beta-cell regeneration and even re-differentiate into local tissues in diabetes mellitus&#xD;
      patients, resulting in improvement of diabetic control, of which the effect may be promoted&#xD;
      by concomitant infusion of bone marrow mononuclear cells and maximized by intra-arterial&#xD;
      pancreatic infusion through angiography.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>January 2009</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>c-peptide area under the curve during OGTT</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The incidence and severity of adverse events related to the stem cell infusion procedure</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The reduction in fasting blood glucose (FBG)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The increase in basal C-peptide</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The reduction in exogenous insulin requirements</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decrease in HbA1c</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>insulin area under the curve during OGTT</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Type 1 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Stem Cell Infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>traditional therapy control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Umbilical mesenchymal stem cell (UC-MSCs) infusion</intervention_name>
    <description>1×10^6/kg UC-MSCs is infused through pancreatic artery along with mononuclear cells by interventional therapy and another same dose of UC-MSCs is administered one week post-intervention.</description>
    <arm_group_label>Stem Cell Infusion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>traditional therapy</intervention_name>
    <description>exogenous insulin injection daily</description>
    <arm_group_label>traditional therapy control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female patients age 18 to 65 years of age.&#xD;
&#xD;
          -  Ability to provide written informed consent.&#xD;
&#xD;
          -  Mentally stable and able to comply with the procedures of the study protocol.&#xD;
&#xD;
          -  Clinical history compatible with type 1 diabetes (T1DM) as defined by the Expert&#xD;
             Committee on the Diagnosis and classification of Diabetes Mellitus&#xD;
&#xD;
          -  Onset of T1DM disease at ≤ 35 years of age.&#xD;
&#xD;
          -  T1DM duration ≥ 2 and ≤ 20 years at the time of enrollment.&#xD;
&#xD;
          -  Basal C-peptide ≤ 0.3 ng/mL&#xD;
&#xD;
          -  HbA1c ≥ 7.5 at time of enrollment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  BMI &gt;35 kg/m^2.&#xD;
&#xD;
          -  Insulin requirements of &gt; 100 U/day.&#xD;
&#xD;
          -  C-reactive protein (hs-CRP) &gt;3.00ng/ml&#xD;
&#xD;
          -  Uncontrolled blood Pressure: SBP &gt;160 mmHg or DBP &gt;100 mmHg at the time of enrollment.&#xD;
&#xD;
          -  Evidence of renal dysfunction, serum creatinine &gt; 1.5 mg/dl (males) and 1.4 mg/dl&#xD;
             (females).&#xD;
&#xD;
          -  Proteinuria &gt; 300 mg/day&#xD;
&#xD;
          -  Evidence of cardiovascular disease, existing congestive cardiac failure on physical&#xD;
             exam and/or acute coronary syndrome in past 6 months.&#xD;
&#xD;
          -  For female participants: Positive pregnancy test, presently breast-feeding, or&#xD;
             unwillingness to use effective contraceptive measures for the duration of the study.&#xD;
             For male participants: intent to procreate 3 months before or after the intervention&#xD;
             or unwillingness to use effective measures of contraception. Oral contraceptives,&#xD;
             Norplant®, Depo-Provera®, and barrier devices with spermicide are acceptable&#xD;
             contraceptive methods; condoms used alone are not acceptable&#xD;
&#xD;
          -  Active infection including hepatitis C, HIV, or TB as determined by a positive skin&#xD;
             test or clinical presentation, or under treatment for suspected TB. Positive tests are&#xD;
             acceptable only if associated with a history of previous vaccination in the absence of&#xD;
             any sign of active infection. Positive tests are otherwise not acceptable, even in the&#xD;
             absence of any active infection at the time of evaluation&#xD;
&#xD;
          -  Known active alcohol or substance abuse including cigarette/cigar smoking&#xD;
&#xD;
          -  Baseline Hemoglobin below the lower limits of normal at the local laboratory;&#xD;
             lymphopenia (&lt;1,000/L), neutropenia (&lt;1,500/L), or thrombocytopenia (platelets&#xD;
             &lt;100,000/L).&#xD;
&#xD;
          -  A history of Factor V deficiency or other coagulopathy defined by INR &gt;1.5, PTT &gt;40,&#xD;
             PT &gt;15.&#xD;
&#xD;
          -  Any coagulopathy or medical condition requiring long-term anticoagulant therapy (e.g.,&#xD;
             warfarin) after transplantation (low-dose aspirin treatment is allowed) or patients&#xD;
             with an INR &gt;1.5.&#xD;
&#xD;
          -  Acute or chronic pancreatitis.&#xD;
&#xD;
          -  Symptomatic peptic ulcer disease.&#xD;
&#xD;
          -  Hyperlipidemia despite medical therapy (fasting LDL cholesterol &gt;130 mg/dl, treated or&#xD;
             untreated; and/or fasting triglycerides &gt; 200 mg/dl).&#xD;
&#xD;
          -  Receiving treatment for a medical condition requiring chronic use of systemic&#xD;
             steroids.&#xD;
&#xD;
          -  Symptomatic cholecystolithiasis.&#xD;
&#xD;
          -  Use of any investigational agents within 4 weeks of enrollment.&#xD;
&#xD;
          -  Admission to hospital for any reason in the 14 days prior to enrollment (signing&#xD;
             consent).&#xD;
&#xD;
          -  Presence of active proliferative diabetic retinopathy or macular edema&#xD;
&#xD;
          -  Any malignancy&#xD;
&#xD;
          -  Abnormal liver function &gt;1.5 x ULN&#xD;
&#xD;
          -  Abdominal aortic aneurysm&#xD;
&#xD;
          -  History of cerebro-vascular accident&#xD;
&#xD;
          -  Any patient with acute or subacute decompensation from diabetes&#xD;
&#xD;
          -  Any acute or chronic infectious condition that in the criteria of the investigator&#xD;
             would be a risk for the patient.&#xD;
&#xD;
          -  Subjects with hypoproteinemia, cachexia or terminal states&#xD;
&#xD;
          -  Subjects with history of anorexia/bulimia&#xD;
&#xD;
          -  Subjects with respiratory insufficiency&#xD;
&#xD;
          -  Any medical condition that, in the opinion of the investigator, will interfere with&#xD;
             the safe completion of the trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jianming Tan, professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fuzhou General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fuzhou General Hospital</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <zip>350025</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <study_first_submitted>June 15, 2011</study_first_submitted>
  <study_first_submitted_qc>June 15, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 16, 2011</study_first_posted>
  <last_update_submitted>November 18, 2012</last_update_submitted>
  <last_update_submitted_qc>November 18, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 20, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>type 1 diabetes mellitus</keyword>
  <keyword>umbilical mesenchymal stem cell</keyword>
  <keyword>mononuclear cell</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

